| Name | Levocetirizine Dihydrochloride |
| Description | Levocetirizine Dihydrochloride (Xyzal Dihydrochloride) is a third-generation peripheral H1-receptor antagonist. Acting as an antihistaminic agent, it specifically targets the histamine H1-receptor. Levocetirizine Dihydrochloride is the R-enantiomer of Cetirizine, which gives it a higher affinity for the H1-receptor than the S-enantiomer. Due to this enhanced affinity, Levocetirizine Dihydrochloride is effective in treating allergic rhinitis and chronic idiopathic urticaria. |
| In vivo | Levocetirizine (0.4 mg/kg; oral administration; male Sprague-Dawley rats) yields a Cmax of 0.34 μg/mL, an AUC0-t of 3.26 μg h/mL, an AUC0-∞ of 3.67 μg h/mL, and a t1/2 of 2.34 hours in Sprague-Dawley rats[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.33 mM), Sonication is recommended. H2O : 90 mg/mL (194.89 mM), Sonication is recommended. DMSO : 50 mg/mL (108.27 mM), Sonication is recommended.
|
| Keywords | Xyzal | Levocetirizine Dihydrochloride | Levocetirizine | HistamineReceptor | Histamine Receptor | H1 receptor | Cetirizine Dihydrochloride | Cetirizine |
| Inhibitors Related | Undecane | Betahistine mesylate | Histamine dihydrochloride | Meclizine dihydrochloride | Lidocaine | Famotidine | Sodium butanoate | Nizatidine | Alginic acid | Mianserin hydrochloride | Trazodone hydrochloride | Doxepin hydrochloride |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |